TY - JOUR
T1 - Immunology of COVID-19
T2 - Current State of the Science
AU - The Sinai Immunology Review Project
AU - Vabret, Nicolas
AU - Britton, Graham J.
AU - Gruber, Conor
AU - Hegde, Samarth
AU - Levantovsky, Rachel
AU - Pia, Luisanna
AU - Saffern, Miriam
AU - Salomé, Bérengère
AU - Tan, Jessica
AU - van der Heide, Verena
AU - Alexandropoulos, Konstantina
AU - Bhardwaj, Nina
AU - Brown, Brian D.
AU - Greenbaum, Benjamin
AU - Gümüş, Zeynep H.
AU - Homann, Dirk
AU - Horowitz, Amir
AU - Kamphorst, Alice O.
AU - Curotto de Lafaille, Maria A.
AU - Mehandru, Saurabh
AU - Merad, Miriam
AU - Samstein, Robert M.
AU - Agrawal, Manasi
AU - Aleynick, Mark
AU - Brown, Matthew
AU - Casanova-Acebes, Maria
AU - Cody, Evan
AU - Fernandez, Nicolas
AU - Grout, John
AU - Ruan, Dan Fu
AU - Humblin, Etienne
AU - Jha, Divya
AU - Lin, Matthew
AU - Lindblad, Katherine
AU - Lubitz, Gabrielle
AU - Noel, Justine
AU - O'Donnell, Tim
AU - Pothula, Venu
AU - Redes, Jamie
AU - Reyes Torres, Ivan
AU - Shang, Joan
AU - Suprun, Maria
AU - Tran, Michelle
AU - Vaninov, Natalie
AU - Aguirre-Ghiso, Julio
AU - Bogunovic, Dusan
AU - Faith, Jeremiah
AU - Grasset, Emilie
AU - Heeger, Peter
AU - Kenigsberg, Ephraim
AU - Krammer, Florian
AU - Laserson, Uri
N1 - Funding Information:
We apologize to all authors whose work we could not cite due to space limitations. Trainee (PhD and MD/PhD or postdocs) and faculty contributing authors are listed in alphabetical order. Illustrations are by Jill K. Gregory and used with permission of Mount Sinai Health System. We would like to acknowledge funding sources including Fastgrant (M.M.), NCI Cancer Center Support Grant Supplement (M.M. R.M.S.) Burroughs Wellcome Fund (R.M.S.), NIH Director's Early Independence Award (R.M.S.) and NIH R01AI081848 (N.V. N.B. B.D.G.). N.B. serves as an advisor/board member for Neon, Checkpoint Sciences, Primevax, Novartis, Array BioPharma, Roche, Avidea, Boeringer Ingelheim, Rome Therapeutics, Roswell Park, and the Parker Institute for Cancer Immunotherapy. N.B. receives research support from the Parker Insitute, Novocure, Celldex, Genentech, Oncovir, and Regeneron. M.M. serves as an advisor/board member for Celsius, Pionyr, Compugen, Myeloids and Innate pharma and ad hoc for Takeda. M.M. receives research support from Regeneron, Takeda, and Genentech. A.M. has equity in Gilead Sciences and Regeneron Pharmaceuticals.
Funding Information:
We apologize to all authors whose work we could not cite due to space limitations. Trainee (PhD and MD/PhD or postdocs) and faculty contributing authors are listed in alphabetical order. Illustrations are by Jill K. Gregory and used with permission of Mount Sinai Health System. We would like to acknowledge funding sources including Fastgrant (M.M.), NCI Cancer Center Support Grant Supplement (M.M., R.M.S.) Burroughs Wellcome Fund (R.M.S.), NIH Director’s Early Independence Award (R.M.S.) and NIH R01AI081848 (N.V., N.B., B.D.G.).
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/6/16
Y1 - 2020/6/16
N2 - The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected millions of people worldwide, igniting an unprecedented effort from the scientific community to understand the biological underpinning of COVID19 pathophysiology. In this Review, we summarize the current state of knowledge of innate and adaptive immune responses elicited by SARS-CoV-2 infection and the immunological pathways that likely contribute to disease severity and death. We also discuss the rationale and clinical outcome of current therapeutic strategies as well as prospective clinical trials to prevent or treat SARS-CoV-2 infection.
AB - The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected millions of people worldwide, igniting an unprecedented effort from the scientific community to understand the biological underpinning of COVID19 pathophysiology. In this Review, we summarize the current state of knowledge of innate and adaptive immune responses elicited by SARS-CoV-2 infection and the immunological pathways that likely contribute to disease severity and death. We also discuss the rationale and clinical outcome of current therapeutic strategies as well as prospective clinical trials to prevent or treat SARS-CoV-2 infection.
UR - http://www.scopus.com/inward/record.url?scp=85085607706&partnerID=8YFLogxK
U2 - 10.1016/j.immuni.2020.05.002
DO - 10.1016/j.immuni.2020.05.002
M3 - Review article
C2 - 32505227
AN - SCOPUS:85085607706
SN - 1074-7613
VL - 52
SP - 910
EP - 941
JO - Immunity
JF - Immunity
IS - 6
ER -